News Matricelf Ltd

Stocks

MTLF

IL0011767915

Biotechnology & Medical Research

Delayed TEL AVIV STOCK EXCHANGE 08:49:15 2026-10-06 EDT			5-day change	1st Jan Change
255.30 ^ILa	+3.86%		-0.04%	-53.66%

09-03	Matricelf Receives FDA Feedback Supporting Key Elements Of Proposed First In Human Clinical Trial For NewRal Spinal Cord Injury Program	CI
08-27	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI

All News

Mentions Relevance

09:01am	Matricelf to Meet Investment Banks at NIBA's 153rd Investment Conference Ahead of Planned Nasdaq Dual Listing and First in Human Studies	AQ
09-03	Matricelf Receives FDA Feedback Supporting Key Elements Of Proposed First In Human Clinical Trial For NewRal Spinal Cord Injury Program	CI
09-03	Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human Clinical Trial for NewRal Spinal Cord Injury Program	PR
08-27	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-09	Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study	CI
07-09	Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones	PR
06-23	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury	AQ
06-22	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI
06-17	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant	CI
03-30	Matricelf Ltd. Enters into Collaborative Research Agreement with CiRA Foundation	CI
03-24	Matricelf Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-24	Matricelf and Sheba Medical Center Enter Strategic Collaboration to Advance First in Human Clinical Program in Spinal Cord Injury	CI
03-23	Matricelf Ltd Auditor Raises 'Going Concern' Doubt	CI
03-04	Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant	CI
03-03	Matricelf Ltd. Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	CI
03-03	Matricelf Ltd. (Tase Mtlf) signs MoU to establish subsidiary for commercialization of Parkinson's disease therapy	RE
03-03	Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	PR
03-02	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	AQ
02-27	Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors	CI
02-27	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	PR
02-26	Matricelf Ltd. (TASE: MTLF) Reports 2025 Milestones and Outlines 2026 Strategic Roadmap Toward First-in-Human Spinal Cord Implantation	PR
25-08-21	Tel Aviv University: Israeli Breakthrough: First Human Trial of Engineered Spinal Cord	AQ
25-08-03	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-03-12	Cellino and Matricelf, New Hope for Spinal Cord Injuries	AQ
25-03-11	Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments	CI